Therapeutics: CD40; Fcγ receptor IIb (FCγR2B; CD32B); FCγR2A (CD32A)

Cancer

INDICATION: Cancer

In vitro and mouse studies suggest a CD40-targeting mAb with greater affinity for FCγR2B than for

Read the full 170 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE